Medrio, a global leader in clinical trial technology, announced the release of AI-enabled reporting, an innovative new capability available within Medrio CDMS/EDC. Medrio’s AI-enabled reporting will simplify data exploration with machine learning and natural language prompts, enabling faster data visualizations and insight discovery.
“Our AI-enabled reporting alleviates the pressures on study teams to manage vast amounts of clinical trial data,” said Mike Stocks, Chief Technology Officer at Medrio. “By overhauling our reporting capabilities and embedding machine learning into our CDMS/EDC platform, we are equipping study teams with the tools to extract meaningful insights quickly. As a result, trials can move forward without unnecessary and often costly delays.”
Clinical trials are generating more data than ever before, increasing the time and costs required for data cleaning and analysis. With the daily costs of clinical trials running into the tens of thousands, delays can quickly strain budgets and extend timelines. As data demands grow, the industry faces mounting pressure to balance efficiency with maintaining data integrity and regulatory standards.
Also Read: eClinicalWorks AI and Sunoh.ai Boost Patient Care in Springfield
“Each clinical study brings with it its own challenges, both in operations and data management,” said Bill Trembley, Senior Vice President and Chief Technology Officer at Beaufort, a MedTech-focused contract research organization. “The sheer volume and complexity of study data warrants the need for robust tools to ensure goals around safety, integrity, and efficiency continue to be met. These significant enhancements have the potential to dramatically improve how quickly we can identify trends and track progress, allowing us to provide our clients with more timely and actionable insights.”
Six industry-leading sponsors and CROs in Medrio’s Early Adopter Program are guiding the development of its AI-enabled reporting. Program members, including Beaufort and LumaBridge, offer vital feedback to help refine Medrio’s reporting capabilities and address the evolving demands of clinical trials. Insights from Early Adopters provide context for natural language prompts and data visualization features, making Medrio’s AI-enabled reporting both practical and impactful for end users.
“Our team at LumaBridge has valued Medrio’s collaborative approach,” said Andrew Milczarek, Director of Clinical Data Management at LumaBridge, an oncology-focused clinical contract research organization. “This capability allows us to maximize efficiency in decision-making rather than spending time re-arranging data. It’s a testament to Medrio and LumaBridge’s commitment to listening to their customers and implementing innovative solutions.”
Source: PRNewswire
